Mouse Anti-Human VEGFR-2/KDR
Slide this table
|Reconstitution||Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.|
|Stability and Storage||The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.|
|Preparation||The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular KDR (110 kDa) as the immunizing antigen.|
|Antigen||recombinant human soluble extracellular KDR (D7)|
|Application||ELISA, IHC, FC, WB|
|Synonyms||vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor|
|Description||VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.|
- Multicolor Immunofluorescent Imaging of Complex Cellular Mixtures on Micropallet Arrays Enables the Identification of Single Cells of Defined Phenotype. T. M. Westerhof et al., Adv Healthc Mater. 2016 Apr 6; 5(7): 767–771.
- Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Elzafir Elsheikh et al., Blood 2005 106:2347-2355.
- Expression of Vascular Endothelial Growth Factor Receptor-2 or Tie-2 on Peripheral Blood Cells Defines Functionally Competent Cell Populations Capable of Reendothelialization. Grzegorz Nowak et al., Circulation. 2004 Dec 14;110(24):3699-707.
All prices plus VAT + possible delivery charges